The MK results demonstrate my points from long ago that CLE has limited application in the upper and lower GI tract as high definition endoscopy which is achievable in most if not all endoscopy centres (e.g. all new Olympus scopes are HD) is actually quite sensitive for dysplastic change, and it is unlikely that the great majority of endoscopists are going to rely on their own histopathology skills when there are paid histopathologists in their hospitals. The major scope manufacturers understand this. MK are saturating their potential markets which are centres which need new technology as a selling point to patients, hence the fall off in sales. From a clinical perspective, the current area of need is the identification of lesions in the biliary tree and pancreas which you can't get a direct look at with the scope. There are a number of competing technologies in this regard including CLE, none of which currently fit the bill of a gold standard.
- Forums
- ASX - By Stock
- OIL
- It`s taken awhile
It`s taken awhile, page-13
Featured News
Add OIL (ASX) to my watchlist
(20min delay)
|
|||||
Last
22.0¢ |
Change
-0.010(4.35%) |
Mkt cap ! $183.7M |
Open | High | Low | Value | Volume |
23.0¢ | 23.0¢ | 21.5¢ | $30.33K | 137.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 21.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.0¢ | 20823 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 0.210 |
2 | 35000 | 0.205 |
1 | 25000 | 0.200 |
3 | 35179 | 0.195 |
3 | 65000 | 0.190 |
Price($) | Vol. | No. |
---|---|---|
0.220 | 20823 | 3 |
0.230 | 106166 | 2 |
0.235 | 91139 | 1 |
0.240 | 74000 | 4 |
0.245 | 149500 | 4 |
Last trade - 13.34pm 16/07/2024 (20 minute delay) ? |
Featured News
OIL (ASX) Chart |